Clinical trial researching immunotherapy for cervical cancer
A clinical trial led by James L. Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology, is researching combination immunotherapy for cervical cancer.
Related Articles
China’s NMPA clears country’s first mesenchymal stem cell therapy
China’s health regulator gave conditional approval to Platinum Life Excellence Biotech Co. Ltd.’s amimestrocel injection (hUC-MSC PLEB-001, Ruibosheng) as the nation’s first human umbilical cord-derived…
NCI Researchers Test Generalizability of Artificial Intelligence (AI) Model | CBIIT
The hallmark of a good AI model is its ability to work the same in different groups, settings, and situations. See how these NCI researchers…
FDA Considers TAR-200 in BCG-Unresponsive High-Risk NMIBC
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time oncology review, expediting access to this potential treatment.
Developing a tumor-specific vaccine for pancreatic cancer in the future
Karen Geboes, MD, PhD, UZ Gent – University Hospital Ghent, Ghent, Belgium, emphasizes the need for higher cure rates in patients with resectable pancreatic cancers.…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Automated Breast Density Assessment for Full-Field Digital Mammography and Digital Breast Tomosynthesis
The proposed model can reduce interobserver variability in BI-RADS density assessment, thereby providing more standard and consistent density assessment for use in decisions about supplemental…
Volume 85 Issue 2 | Cancer Research | American Association for Cancer Research
Cancer Research | 85 | 2 | January 2025
Economic Evaluation of ‘Watch and Wait’ Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review
Annals of Surgical Oncology – Owing to multimodal treatment and complex surgery, locally advanced rectal cancer (LARC) exerts a large healthcare burden. Watch and wait…
Research to Watch: Lurbinectedin-Atezolizumab Combination Demonstrates Significant OS, PFS Benefits – ILCN.org (ILCN/WCLC)
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC.
